S. Kizhake

发表

Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design.

Nicholas Y. Palermo, Eric A. Kumar, S. J. Campbell, 2011, ACS medicinal chemistry letters.

Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth

Ayrianne J. Crawford, G. Borgstahl, M. Hollingsworth, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain.

Nicholas Y. Palermo, Eric A. Kumar, G. Borgstahl, 2012, Journal of medicinal chemistry.

Dimers of isatin derived α-methylene-γ-butyrolactone as potent anti-cancer agents.

T. Huxford, Sandeep Rana, A. Natarajan, 2022, Bioorganic & medicinal chemistry letters.

Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.

Sandeep Rana, Jacob I. Contreras, A. Natarajan, 2021, European journal of medicinal chemistry.

Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.

Nicholas T. Woods, M. Naldrett, Sandeep Rana, 2021, Bioorganic & medicinal chemistry letters.

Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK.

Sandeep Rana, Jacob I. Contreras, A. Natarajan, 2020, Chemical biology & drug design.

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

Ayrianne J. Crawford, M. Hollingsworth, M. Bendjennat, 2019, Molecular Pharmacology.

Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design

Wanli You, Chia-en A. Chang, Smitha Kizhake, 2016, PLoS Comput. Biol..

Small molecule binding to inhibitor of nuclear factor kappa-B kinase subunit beta in an ATP non-competitive manner.

Nicholas Y. Palermo, T. Huxford, M. Ouellette, 2021, Chemical communications.

Selective degradation of CDK6 by a palbociclib based PROTAC.

M. Bendjennat, Sandeep Rana, A. Natarajan, 2019, Bioorganic & medicinal chemistry letters.

Spirocyclic dimer SpiD7 activates the unfolded protein response to selectively inhibit growth and induce apoptosis of cancer cells

Nicholas T. Woods, Sandeep Rana, A. Natarajan, 2022, The Journal of biological chemistry.

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

M. Hollingsworth, J. Black, M. Brattain, 2017, Oncotarget.

Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1

Claudio N. Cavasotto, Victor M. Anisimov, Arturas Ziemys, 2011, J. Comput. Aided Mol. Des..

Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.

Sandeep Rana, A. Natarajan, M. Zahid, 2018, Bioorganic & medicinal chemistry letters.

The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides

Eric A. Kumar, G. Borgstahl, A. Natarajan, 2013, Scientific Reports.

Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.

Sandeep Rana, Jacob I. Contreras, A. Natarajan, 2016, Journal of medicinal chemistry.

Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy.

Ayrianne J. Crawford, M. Hollingsworth, Sandeep Rana, 2018, ACS chemical biology.

Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1.

Eric A. Kumar, A. Natarajan, Ziyan Yuan, 2011, Journal of medicinal chemistry.

Structural characterization of BRCT-tetrapeptide binding interactions.

Eric A. Kumar, K. Rajarathnam, A. Natarajan, 2010, Biochemical and biophysical research communications.